arrow
Z

Zeev Estrov

ut md anderson cancer center
H指数:102
被引数:4.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

原发性骨髓纤维化进展过程中骨髓纤维细胞的时间动态

BLOOD
IF23.1
2024-11-050
PRE
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study
2024-04-0411
OAAI
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2 (vol 9, e121781, 2020)
2024-02-081
PRE
Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis
2021-08-2018
OA
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia

氯法拉滨或克拉屈滨联合低剂量阿糖胞苷与地西他滨交替低强度化疗治疗老年急性髓系白血病的长期疗效

2021-05-2618
OAAI
Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
LEUKEMIA
IF13.4
2021-05-1827
PREAI
Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia
CANCER
IF5.1
2021-04-2912
OAAI
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
2021-04-1546
OAAI
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
LEUKEMIA
IF13.4
2021-04-1222
PREAI
Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission
CANCER
IF5.1
2021-01-158
OAAI
Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia
2020-11-2115
PREAI
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

为期10天的地西他滨联合维奈托克治疗新诊断的不合格强化化疗和复发或难治性急性髓系白血病: 一项单中心2期临床试验

2020-10-01236
OAAI